BioSpace News Archive

TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today reported financial results for its second quarter ending June 30, 2020.

Berkshire Biomedical, LLC (“Berkshire” or “the Company”), a privately-held digital health company developing a revolutionary virtual care and prescription drug management system for the Intended User, today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. patent application No. 16/420,002 relating to the Company’s Computerized Prescription Administration (COPA™) system

Can-Fite BioPharma Ltd. announced it will conduct a conference call with investors to review financial results of its second quarter and provide an update on clinical and corporate developments, including its advanced stage drug candidates Piclidenoson and Namodenoson.

Enanta Pharmaceuticals, Inc. announced that clinical data from Enanta’s wholly-owned development programs for non-alcoholic steatohepatitis and hepatitis B virus have been accepted for presentations at the European Association for the Study of the Liver Digital International Liver Congress 2020 being held August 27-29, 2020.

LAIX Inc. (“LAIX” or the “Company”) (NYSE: LAIX), an artificial intelligence (AI) company in China that creates and delivers products and services to popularize English learning, today announced that it will report its second quarter 2020 unaudited financial results on Wednesday, August 26, 2020, after the close of the U.S. markets.

Conformis, Inc. (NASDAQ:CFMS) announced today that it completed the second of three milestones pursuant to the License Agreement and Development Agreement with Howmedica Osteonics Corp., a wholly owned subsidiary of Stryker Corporation also known as Stryker Orthopaedics, under which Conformis is developing patient-specific instrumentation (“PSI”) for use in connection with Stryker’s knee implant offerings. The Company will receive an addition

Oral Presentation to Highlight New Efficacy Data Measured at Week 16 and Additional Week 12 Efficacy Data Stratified by Baseline Characteristics and Risk Factors

Newtopia Inc. (TSXV: NEWU), a tech-enabled disease prevention company focused on healthy habit change, today announced it is offering an expanded product suite that targets hypertension, type 2 diabetes and weight

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced an upcoming late-breaker poster presentation at The Digital International Liver Congress™ 2020 (EASL), which is being held virtually from August 27 to 29. This presentation will discuss key data from A

With the rise in hospital acquired infections and rising awareness regarding the prevention of viruses the bio contamination market is expected to grow leaps and bounds during the forecast period.